Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00631917 |
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Aliskiren Drug: Ramipril |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 54 Week, Randomized, Double-Blind, Parallel-Group, Multicenter Study Evaluating the Long-Term Gastrointestinal (GI) Safety and Tolerability of Aliskiren (300 mg) Compared to Ramipril (10 mg) in Patients With Essential Hypertension |
Estimated Enrollment: | 640 |
Study Start Date: | February 2008 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Aliskiren 150mg, or 300mg, oral, once per day.
|
Drug: Aliskiren
Aliskiren 150mg, or 300mg, oral, once per day.
|
2: Active Comparator
Ramipril 5mg, or 10 mg, oral, once per day
|
Drug: Ramipril
Ramipril 5mg, or 10 mg, oral, once per day
|
Ages Eligible for Study: | 50 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Missouri | |
Investigative Site | |
Kansas City, Missouri, United States | |
Argentina | |
Investigative Site | |
Investigative Site, Argentina | |
Colombia | |
Investigative Site | |
Investigative Site, Colombia | |
France | |
Investigative Site | |
Investigative Site, France | |
Germany | |
Investigative Site | |
Investigative Site, Germany | |
India | |
Investigative Site | |
investigative Site, India | |
Peru | |
Investigative Site | |
Investigative Site, Peru | |
Spain | |
Investigative Site | |
Investigative Site, Spain |
Study Chair: | Novartis | 862-778-8300 |
Responsible Party: | Novartis ( Novartis ) |
Study ID Numbers: | CSPP100A2404 |
Study First Received: | March 3, 2008 |
Last Updated: | August 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00631917 |
Health Authority: | United States: Food and Drug Administration |
Hypertension,aliskiren, ramipril, colonoscopy |
Vascular Diseases Essential hypertension Ramipril Hypertension |
Molecular Mechanisms of Pharmacological Action Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Enzyme Inhibitors Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Protease Inhibitors |